English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 24 November 2022, 9:04 JST
Share:
    

Source: Eisai
Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting

TOKYO, Nov 24, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will have a total of 34 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) at the 76th American Epilepsy Society Annual Meeting (AES 2022), to be held in Nashville, Tennessee and virtually from December 2-6, 2022.

Key data Presentations for perampanel include the:
- Results from a post hoc analysis of the phase III clinical trial (FREEDOM/342), which evaluated long-term efficacy of perampanel monotherapy by seizure type in the open-label extension (52 weeks) for epilepsy patients with focal-onset seizures (FOS), ≥ 12 years of age without prior treatment history (poster number: 2.228)
- Real-world pooled analyses of perampanel for pediatric patients (poster number: 1.310),
adolescent patients (poster number: 1.313) and elderly patients (poster number: 1.312)
- Results from a post hoc analysis of two phase III open-label extension (OLEx) studies, Study 307 and Study 335 OLEx, evaluating the long-term efficacy and safety of adjunctive perampanel in a subgroup of older adult patients aged ≥ 60 years (poster number: 1.291)

"With 34 poster presentations planned for this year's AES Meeting, we look forward to furthering our understanding of the results that may impact overall care in epilepsy," said Ivan Cheung, Senior Vice President Global Alzheimer's Disease Officer President, Americas Region, Eisai Co., Ltd., "We remain focused on addressing the diverse needs of patients with epilepsy and their families."

Perampanel is a first-in-class AED discovered by Eisai's Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper- excitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. The agent is currently approved for partial-onset seizures (with or without secondarily generalized seizures) in over 70 countries including Japan, the United States, China and other countries in Europe and in Asia. The agent is currently approved as an adjunctive therapy for primary generalized tonic-clonic seizures in over 70 countries including Japan, the United States, and other countries in Europe and in Asia.

Eisai considers neurology, including epilepsy, a therapeutic area of focus. Eisai pursues its mission to provide "seizure freedom" to a greater number of patients with epilepsy. Eisai remains committed further to addressing the diverse needs of, and increasing the benefits provided to, patients with epilepsy and their families

For more information, visit www.eisai.com/news/2022/pdf/enews202281pdf.pdf.

Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
2022年11月24日 9時00分 JST
エーザイ、第76回米国てんかん学会年次総会にてペランパネルに関する最新データを発表
2022年11月22日 14時00分 JST
島津製作所・エーザイ・大分大学・臼杵市医師会、日本初となる血液バイオマーカーを用いた認知症診断ワークフローの構築へ
Tuesday, 22 November 2022, 14:10 JST
To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
Monday, 21 November 2022, 11:50 JST
Eisai to Present Full Findings from Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) and Other Alzheimer's Disease Research at The 15th Clinical Trials on Alzheimer's Disease (CTAD) Conference
2022年11月21日 10時30分 JST
エーザイ、第15回アルツハイマー病臨床試験会議(CTAD)において抗アミロイドβ(Aβ)プロトフィブリル抗体レカネマブの臨床第III相Clarity AD検証試験の詳細結果を含むアルツハイマー病領域のパイプラインに関する最新データを発表
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575